Raytheon Wins Up to $24.4 Billion SM-6 Contract as Lilly, Integra and Trilogy Report Developments

Stock Preachers··US·Read original
3▲3 ▼2Impact / 5
Summary · why it matters

Raytheon, an RTX business, secured a five-year contract with two additional option years valued up to $24.4 billion for Standard Missile-6 interceptors for the U.S. Navy. Raytheon President Phil Jasper said SM-6's multi-mission capability is vital to the customer and that the company is removing constraints and boosting capacity. The FDA approved an expanded indication for Eli Lilly's Jaypirca, or pirtobrutinib, as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion, based on the BRUIN CLL-313 trial, where progression-free survival improved with a hazard ratio of 0.20 and overall response rate was 94% versus 81% in the comparator arm. Hagens Berman Sobol Shapiro is investigating IBM after shares fell 25% on July 14, 2026, erasing more than $68 billion in market capitalization following disclosure of a shortfall in the company's Z mainframe performance. Integra LifeSciences lowered its full-year 2026 guidance after a July flooding event at its Cincinnati facility, now expecting third quarter revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59, with full-year revenue guidance cut to a range of $1.634 billion to $1.654 billion from $1.654 billion to $1.695 billion and adjusted EPS guidance lowered to $2.30 to $2.40 from $2.40 to $2.50. Trilogy Metals reported a cash balance of $31.2 million and adjusted working capital of $30.3 million as of August 31, 2026, along with the closing of a $35.6 million strategic equity investment from the Department of War on September 11, 2026, and net income of $0.2 million for the third quarter compared to a net loss of $1.7 million a year earlier.

Impact on assets 5

Biotech & Genomic Medicine± Mixed
Eli Lilly and Company
LLY
▲ PositiveRegulationrelevance

FDA approved an expanded first-line indication for Eli Lilly's Jaypirca (pirtobrutinib) in CLL/SLL.

Defense & Geopolitical Fragmentation▲
RTX Corporation
RTX
▲ PositiveDemandrelevance

Raytheon won a five-year U.S. Navy contract worth up to $24.4 billion for Standard Missile-6 interceptors.

Critical Materials & Supply Chain▲
Trilogy Metals Inc
TMQ
▲ PositiveCapitalrelevance

Trilogy Metals closed a $35.6 million strategic equity investment from the Department of War and reported net income of $0.2 million.

Quantum Computing▼
International Business Machines
IBM
▼ NegativeTechnologyrelevance

Hagens Berman is investigating IBM after shares fell 25% following disclosure of a shortfall in its Z mainframe performance.